- Bristol Myers Raises 2026 Sales Forecast After Strong Demand For New Drugs
Bristol Myers Squibb Co. boosted its 2026 sales forecast after the company saw strong demand for its new drugs in the third quarter, including the cancer treatment Opdivo Qvantig.
Guidance·1 article / 1 outlet·20d ago
- Roche Drug Helps Lung Cancer Patients Live Six Months Longer Than Rivals
A Roche Holding AG drug billed as a potential blockbuster helped patients with a form of lung cancer that had spread live almost six months longer than two competitive medicines.
Product·2 articles / 2 outlets·23d ago
- Bristol Myers Reports One CAR-T Death Amid Rising Safety Concerns
Bristol Myers Squibb Co. has reported a death in its clinical trials of an experimental cell therapy for autoimmune diseases, potentially adding to safety concerns about a promising new class of treatments.
Product·2 articles / 2 outlets·26d ago
- Bristol Myers' Drugs Succeed in Treating Lung Disease, Cancer in Late-Stage Studies
Bristol Myers Squibb Co.’s experimental drugs for treating a rare endocrine cancer and a deadly form of lung disease succeeded in late-stage studies. This success is expected to boost the pharmaceutical company’s new product pipeline.
Product·1 article / 1 outlet·37d ago
- AstraZeneca CEO Says No Major Deal Needed for Growth Beyond 2030
AstraZeneca Plc has what it needs to keep growing beyond 2030 without a major acquisition, Chief Executive Officer Pascal Soriot said. This statement comes weeks after speculation about a potential tie-up with Bristol Myers Squibb Co.
Macro·1 article / 1 outlet·44d ago
- Novartis, Bristol Myers Halt Autoimmune CAR-T Trials Due to Safety Concerns
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events. Side effects observed in testing have led Novartis to halt development.
Product·2 articles / 2 outlets·78d ago
- Bristol Myers Wins FDA Approval for Zenbexus, Debuting New Myeloma Drug Class
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs for the blood cancer.
Product·2 articles / 2 outlets·96d ago
- Bristol Myers Squibb Receives FDA Approval for ZENBEXUS in Multiple Myeloma Treatment↩
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma as early as first relapse.
Product·3 articles / 3 outlets·96d ago·◆ Primary source
- Bristol Myers Wins FDA Approval for Zenbexus, Debuting New Myeloma Drug Class
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs, which are designed to target and degrade specific proteins involved in the disease.
Product·2 articles / 2 outlets·96d ago
- Bristol Myers Squibb Receives FDA Approval for First CELMoD Therapy ZENBEXUS for Multiple Myeloma
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs targeting this blood cancer.
Product·3 articles / 3 outlets·96d ago·◆ Primary source
- Bristol Myers Squibb Receives FDA Approval for ZENBEXUS in Multiple Myeloma Treatment
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This approval marks a significant milestone as it is the first for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
Product·3 articles / 3 outlets·96d ago·◆ Primary source
- Bristol Myers Squibb Receives FDA Approval for First CELMoD Therapy ZENBEXUS for Multiple Myeloma
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
Product·3 articles / 3 outlets·96d ago·◆ Primary source